Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator's choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy
Year: 2025
Type: conference-abstract
Source: Blood
Institutions: Austin Health, Université de Versailles Saint-Quentin-en-Yvelines, Institut Curie, Peking University, Peking University Cancer Hospital, Ankara University, Centre Hospitalier Universitaire de Lille, City Of Hope National Medical Center, City of Hope, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Switzerland), University of California, San Francisco
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417020119
Cites:
Cited by:
Related to: